Vestn Otorinolaringol. 2026;91(4):117-124. doi: 10.17116/otorino202691041117.
ABSTRACT
Violations of specific immune defense and weakening of nonspecific resistance of the body during inflammatory diseases of the upper respiratory tract necessitate a complex intervention using I eat drugs with immunomodulatory effects. For practicing doctors, immunomodulators are of particular interest. lators of natural origin obtained from active substances of medicinal plants.
PURPOSE OF THE REVIEW: To analyze the effectiveness of the clinical use of the drug Tonsilgon N for chronic infections. tions of the upper respiratory tract in adult and pediatric patients and its impact on the prevention of exacerbations.
MATERIAL AND METHODS: A search of publications was carried out in the databases PubMed, Embase, Cochrane Library, ClinicalTrials.gov, eLibrary.ru, Google Scholar. The results of randomized and non-randomized controlled trials were analyzed.
observational studies for 2000-2026.
RESULTS: The review included information from 20 studies. The collected data showed the ability of the drug Tonsilgon N increases immunological resistance and prevents the development of exacerbations of chronic infections tions. Analysis of published works indicates the high preventive effectiveness of the drug Tonsilgon N: its use statistically significantly reduces the incidence of acute respiratory viral infections, helps relieve local manifestations of inflammation, reduces the average duration of exacerbations. Decrease noted the need for antibiotic therapy when using the drug Tonsilgon N in children of different age groups and in adults.
CONCLUSION: The research results have convincingly proven the effectiveness of the drug Tonzilgon N in relation to cupping prevention of exacerbations and prevention of relapses of chronic upper respiratory tract infections.
PMID:42693997 | DOI:10.17116/otorino202691041117
